arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

REPLIGEN CORP

RGEN
$163.85 ▲ +4.38 (+2.75%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
68 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
60
Health
Fair
Neutral
auto_awesome

Analytical Summary

REPLIGEN CORP shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $9.2B
Dividend Yield
Revenue Growth 11.9%
Op. Margin 6.8%
ROIC 0.2%
FCF / Share $0.49
Trailing P/E 1820.6x
Price / Book 4.4x
FCF Yield 0.3%
Debt / Equity 0.26
info Valuation on last close. End-of-day price, Aug 7, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$204.13M
↑ +11.9%
Net Income Profit after all expenses
$5.01M
↓ -66.3%
Operating Margin Operating profit as % of sales
6.8%
↓ -16.6% 50th
FCF / Share Free cash flow per share
$0.49
↑ +16.2%
Long-Term Debt Long-term obligations
$551.05M
↑ +0.8%

Health Breakdown

Profitability
57
Returns
48
Financial Health
65
Cash Quality
85

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 68 quarters